You are currently viewing a new version of our website. To view the old version click .

Current Oncology, Volume 29, Issue 10

October 2022 - 104 articles

Cover Story: The combination of an immune checkpoint inhibitor and a multitarget tyrosine kinase inhibitor has become a standard first-line treatment for metastatic renal cell cancer, changing the therapeutic landscape. Along with survival improvement, combination therapy has raised complexity in adverse event handling. Toxicities could be insidious in clinical presentation, and proper attribution to either of the two classes of drugs could be challenging. Key points that clinicians can rely on to achieve an optimal adverse events management are the adherence to immune-related toxicities’ international guidelines, the application of proper expert-defined algorithms, the knowledge sharing within a multidisciplinary dedicated board, and accurate patient information. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (104)

  • Article
  • Open Access
7 Citations
2,793 Views
13 Pages

Cancer Patients First Treated with Chemotherapy: Are They More Likely to Receive Surgery in the Pandemic?

  • Rui Fu,
  • Rinku Sutradhar,
  • Anna Dare,
  • Qing Li,
  • Timothy P. Hanna,
  • Kelvin K. W. Chan,
  • Jonathan C. Irish,
  • Natalie Coburn,
  • Julie Hallet and
  • Simron Singh
  • + 13 authors

14 October 2022

Due to the ramping down of cancer surgery in early pandemic, many newly diagnosed patients received other treatments first. We aimed to quantify the pandemic-related shift in rate of surgery following chemotherapy. This is a retrospective population-...

  • Review
  • Open Access
17 Citations
4,920 Views
14 Pages

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma

  • Laurys Boudin,
  • Jean-Baptiste Morvan,
  • Juliette Thariat,
  • Denis Métivier,
  • Pierre-Yves Marcy and
  • David Delarbre

14 October 2022

Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease. Thyrosine kinase in...

  • Article
  • Open Access
9 Citations
3,617 Views
13 Pages

Clinical Management of Financial Toxicity–Identifying Opportunities through Experiential Insights of Cancer Survivors, Caregivers, and Social Workers

  • Christopher J. Longo,
  • Louisa G. Gordon,
  • Rebecca L. Nund,
  • Nicolas H. Hart,
  • Laisa Teleni,
  • Carla Thamm,
  • Olivia Hollingdrake,
  • Fiona Crawford-Williams,
  • Bogda Koczwara and
  • Tamara Ownsworth
  • + 5 authors

14 October 2022

Perspectives of cancer survivors, caregivers, and social workers as key stakeholders on the clinical management of financial toxicity (FT) are critical to identify opportunities for better FT management. Semi-structured interviews (cancer survivors,...

  • Article
  • Open Access
5 Citations
2,838 Views
10 Pages

Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

  • Siddhartha Goutam,
  • Igor Stukalin,
  • Benjamin Ewanchuk,
  • Michael Sander,
  • Philip Q. Ding,
  • Daniel E. Meyers,
  • Daniel Heng,
  • Winson Y. Cheung and
  • Tina Cheng

14 October 2022

Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elus...

  • Article
  • Open Access
11 Citations
5,612 Views
15 Pages

14 October 2022

Esophageal squamous cell carcinoma (ESCC) is a type of progressive and distant metastatic tumor. Targeting anti-angiogenic genes could effectively hinder ESCC development and metastasis, whereas ESCC locating on the upper or the lower esophagus showe...

  • Feature Paper
  • Article
  • Open Access
4 Citations
2,484 Views
8 Pages

Outcomes of Early Transition of Low-Risk Thyroid Cancer Patients from Specialist to Primary Care

  • Patricia Nguyen,
  • Parsa Azizi-Mehr,
  • Carol Townsley and
  • Afshan Zahedi

14 October 2022

Background: Recently published clinical pathways for management of thyroid cancer outlined the criteria for transitioning low-risk patients to primary care within one to five years from diagnosis. However, discharge patterns among endocrinologists re...

  • Article
  • Open Access
11 Citations
3,533 Views
17 Pages

Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone

  • Mengke Fan,
  • Guochuan Zhang,
  • Mingfang Xie,
  • Xinbo Liu,
  • Qi Zhang and
  • Ling Wang

13 October 2022

The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients. Although the treatment methods for a GCTB, such as scraping and resection, effectively inhibit the...

  • Article
  • Open Access
12 Citations
2,960 Views
10 Pages

13 October 2022

This study aimed to use a new special inventory for lung surgery patients to evaluate postoperative symptoms and functional status and to identify factors that may affect these after uniportal video-assisted thoracoscopic surgery (VATS). In this sing...

  • Case Report
  • Open Access
1 Citations
3,099 Views
8 Pages

Plasmacytic Pleural Effusion as a Major Presentation of Angioimmunoblastic T-Cell Lymphoma: A Case Report

  • Borui Li,
  • Lin Nong,
  • Jianhua Zhang,
  • Wensheng Wang,
  • Qian Wang,
  • Yang Zhang,
  • Shaomin Ren and
  • Mangju Wang

13 October 2022

Angioimmunoblastic T-cell lymphoma is one of the peripheral T-cell lymphomas. Reactive plasma cells can occasionally be observed in AITL patients’ peripheral blood and bone marrow. Plasmacytic pleural effusion as the presentation of AITL has no...

  • Article
  • Open Access
7 Citations
4,040 Views
13 Pages

13 October 2022

Publicly funded healthcare systems, including those in Canada, the United Kingdom (UK), and Australia, often use health technology assessment (HTA) to inform drug reimbursement decision-making, based on dossiers submitted by manufacturers, and HTA ag...

of 11

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729